Aptamers News and Research

RSS

Study finds race-specific lupus nephritis biomarkers for early diagnosis, treatment

University of Houston Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, Chandra Mohan, and his team have discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

6 May 2020

Researchers re-purpose cancer-fighting artificial antibodies for COVID-19

Researcher Paula Bates, John Trent, and Don Miller developed a therapeutic drug that could potentially block the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the COVID-19 pandemic. Their research was initially aimed at helping patients suffering from multiple types of cancer.

27 Apr 2020

Scientists pinpoint protein that plays key role in lung cancer and melanoma progression

Scientists from Far Eastern Federal University, University of Geneva (Switzerland), Minjiang University, and Fuzhou University (China) pointed out WDR74 protein playing an important role in lung cancer and melanoma primary tumors/metastases progression.

16 Feb 2020

Blood proteins could help provide a comprehensive 'liquid health check' in future

Proteins in our blood could in future help provide a comprehensive 'liquid health check', assessing our health and predicting the likelihood that we will we will develop a range of diseases, according to research published today in Nature Medicine.

2 Dec 2019

“Liquid health check” could predict disease risk in the future

Measuring proteins in the blood could serve as a “liquid health check” that could predict people’s risk of developing diseases.

2 Dec 2019

New highly sensitive test for dengue virus developed using DNA star

Researchers have developed a new method for detecting and destroying the dengue virus that could be adapted for other viruses.

25 Nov 2019

DNA-modulated liquid droplets may explain how prion proteins clump

Researchers at the Federal University of Rio de Janeiro, in Brazil, have identified that the interaction between prion proteins and DNA may be behind the formation of protein amyloid aggregates and of the emergence of neurodegenerative diseases such as Creutzfeldt-Jakob disease and other spongiform encephalopathies.

22 Nov 2019

Hong Kong Baptist University receives FDA orphan drug designation for novel aptamer

A research team from the School of Chinese Medicine at Hong Kong Baptist University has successfully developed a novel aptamer, i.e. a single-stranded piece of DNA, for the treatment of osteogenesis imperfecta (OI) with the aid of artificial intelligence (AI) technology.

23 Oct 2019

Researchers synthesize artificial cells to detect histamine

Baking a cake from scratch is a task deemed difficult for many. Constructing an artificial cell-like system from scratch, well that's another story.

3 Jul 2019

Aptamer Therapeutics collaborates with Cancer Research UK for drug development program

Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby Leukemia Research Program at the University of Manchester and Cancer Research UK.

From Aptamer Group 6 May 2019

SibFU scientists create multilayer gilded nanodisks for medical applications

Young scientists from SibFU together with their colleagues from FRC KSC SB RAS are developing a technology for creating multilayer gilded nanodisks for targeted drug delivery and treating malignant tumors using dip pen nanolithography.

24 Apr 2019

Q BioMed and Mannin Research collaborate with McMaster University to develop GDF15 biomarker glaucoma diagnostic kit

Q BioMed Inc., a commercial stage biotechnology acceleration development company, announced today that its technology partner Mannin Research Inc. has entered into a research collaboration with the Biointerfaces Institute at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression.

From Q BioMed Inc. 21 Mar 2019

Base Pair Biotechnologies to develop point-of-care tests for opioids in newborns

Base Pair Biotechnologies announced today the receipt of a Fast Track Small Business Innovation Research grant from the National Institute on Drug Abuse of the NIH

From Base Pair Biotechnologies, Inc. 25 Feb 2019

Aptamer Group and AstraZeneca to develop new drug delivery vehicles

Aptamer Group today announced it has signed an agreement with AstraZeneca to explore the potential of using aptamer technology to target the kidney.

From AstraZeneca 10 Jan 2019

New bioinspired material interacts with surrounding tissues to promote wound healing

Imperial researchers have developed new bioinspired material that interacts with surrounding tissues to promote healing.

7 Jan 2019

New technique detects, measures, analyzes unevenly charged biomolecules

In clinical diagnostics, it is critical to monitor biomolecules in a simple, rapid and sensitive way. Clinicians most often monitor antibodies because these small proteins attach to antigens, or foreign substances, we face every day.

17 Aug 2018

Researchers show how specialized nucleic acid-based nanostructures could help target cancer cells

More than 100 years ago, German Nobel laureate Paul Ehrlich popularized the "magic bullet" concept -- a method that clinicians might one day use to target invading microbes without harming other parts of the body. Although chemotherapies have been highly useful as targeted treatments for cancer, unwanted side effects still plague patients.

14 Aug 2018

A Multi-Modal Approach for the Early Detection of Breast Cancer

Professor Samir Iqbal describes his research in the field of breast cancer detection and how machine learning can improve early diagnosis rates.

16 Jul 2018

Researcher develops nanoparticle-based tags to detect viruses and cancer with high sensitivity

How can we detect cancer and viruses with high sensitivity? Physical chemist Laura Fabris-;an associate professor in the Materials Science and Engineering Department at Rutgers, the State University of New Jersey, and principal investigator of the Fabris NanoBio Group-;is addressing this very question.

22 May 2018

UC scientists identify protein that acts as mediator of HER2-driven breast cancer

Researchers at the University of Cincinnati College of Medicine have identified for the first time that the estrogen receptor-binding protein MED1 is a critical mediator of HER2-driven breast cancer, identifying it as a potential therapeutic target.

9 Jan 2018